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ABSTRACT 
 
 Seventeen yearling Quarter Horses were used in a randomized complete 
block design for a 56 d trial to determine ability of dietary conjugated linoleic acid 
(CLA) to reach circulating levels in plasma and mitigate joint inflammation and 
cartilage turnover.  Horses were blocked by age, sex and BW and randomly assigned 
to treatments consisting of a commercial concentrate offered at 1% BW (as-fed) 
supplemented with either 1% soybean oil (CON; n = 6), 0.5% soybean oil and 0.5% 
CLA (LOW; n = 5; Lutalin
®
, BASF Corp.), or 1% CLA (HIGH; n = 6; 55% purity) 
top-dressed daily.  Horses were fed individually every 12 h and offered 1% BW 
daily (as-fed) coastal bermudagrass (Cynodon dactylon) hay.   
This study was separated into two phases: phase 1 determined incorporation 
of CLA to circulating levels in plasma; phase 2 evaluated the potential of CLA to 
mitigate induced intra-articular inflammation and cartilage metabolism stimulated 
by lipopolysaccharide (LPS).  Phase 1 comprised the first 41 d.  Phase 2 began on d 
42 and extended to d 56.  Weekly, beginning at d 0, physical growth measurements 
were recorded and blood samples were collected and analyzed for fatty acid 
concentrations.  
 On d 42, an LPS challenge was conducted.  Carpal joints within each horse 
were randomly assigned to receive intra-articular injections of 0.5 ng LPS derived 
from Escherichia coli 055:B5 or sterile lactated Ringer’s solution as a contralateral 
control.  Synovial fluid samples were obtained via arthrocentesis at pre-injection h 0 
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and 6, 12, 24, 168 and 336 h post-injection, and subsequently analyzed by ELISA 
for prostaglandin E2 (PGE2), carboxypeptide of type II collagen (CPII), and 
collagenase cleavage neopeptide (C2C).  Vitals were monitored at 0, 6, 12 and 24 h; 
and carpal circumference and surface temperatures were also recorded.  All data 
were analyzed using PROC MIXED procedure of SAS.    
 All physical measurements increased (P < 0.01) over time with no influence 
of CLA supplementation.  Isomers of CLA were detectable in plasma by d 14, and 
HIGH horses had greatest concentrations (P < 0.04).  Horses fed CON had 
undetectable levels of CLA.  Arachidonic acid levels were lower (P < 0.06) in 
HIGH horses compared to both LOW and CON.  Vitals were not different across 
dietary treatments (P > 0.13) and remained within normal.   
Synovial PGE2 was not affected by dietary treatment (P = 0.15).  Synovial 
C2C responded to dietary treatment (P = 0.05) with HIGH horses having lower C2C 
than LOW.  There was an effect (P < 0.01) of time with C2C values peaking 
between h 12 and 24, and decreasing by h 336.  Levels of CPII tended to be 
influenced by dietary treatment (P = 0.10) with LOW horses having greater CPII 
compared to CON, and HIGH horses were intermediate with no difference from 
CON or LOW.  Regardless of diet, CPII increased to h 24 (P < 0.01) and decreased 
to h 336.  In conclusion, dietary CLA reached circulating levels in plasma prior to 
the LPS challenge.  Dietary CLA supplementation did not influence PGE2; however, 
horses receiving CLA had lesser C2C and greater CPII, indicating less degradation 
and greater synthesis of cartilage in response to an acute inflammatory condition.   
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CHAPTER I 
 INTRODUCTION 
 
Osteoarthritis (OA) is the leading cause of lameness in the horse and is 
characterized by the degradation of articular cartilage (Rossdale et al., 1985).  Often, 
detrimental changes to articular cartilage occur because of recurring inflammation 
caused by trauma or overloading to the synovial joint (McIlwraith et al., 2012).  When 
an inflammatory response is initiated, macrophages are recruited to the site of damage 
and release cytokines including Interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-α; 
McIlwraith, 1996).  These cytokines stimulate cells of the synovium and articular 
cartilage, synoviocytes and chondrocytes, respectively, to produce and release matrix 
metalloproteinases (MMPs) and eicosanoids, including Prostaglandin E2 (PGE2; 
McIlwraith et al., 2012).   
These products of inflammation can be released into the synovial fluid within the 
joint cavity.  When an animal moves, articular cartilage acts as a sponge and absorbs 
cytokines, eicosanoids and MMPs (Caola, 2003).  When articular cartilage is exposed to 
these inflammatory products, the response is the breakdown of articular cartilage and 
degradation of the extracellular matrix.  When the fibrous portion of articular cartilage, 
type II collagen, is broken down, hidden epitopes are exposed and can be used as 
biomarkers to measure the metabolism of articular cartilage (Poole, 1992).  One such 
epitope is collagenase cleavage neoepitope (C2C), which has been successfully used as a 
measurement of cartilage degradation in the horse (Lucia et al., 2013; de Grauw et al., 
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2009).  The use of such biomarkers is beneficial to diagnosis since current radiographic 
imaging cannot detect early stages of OA.  As such, current treatments are used to mask 
the pain of already present OA, and include non-steroidal anti-inflammatory drugs 
(NSAIDS), intra-articular corticosteroids, and IV or IM polysulfated 
glycosaminoglycans (PSGAGs).   
With the discovery of reliable biomarkers to measure inflammation and cartilage 
metabolism such as PGE2, C2C and carboxypeptide of type II collagen (CPII), current 
research has focused on options to mitigate inflammation through dietary 
supplementation.  One method that has been extensively researched is through the use of 
polyunsaturated fatty acids.  These are most commonly supplemented as ω-3 fatty acids 
in the form of fish oil or flaxseed oil.  They have been found to successfully reduce 
cytokine production and alter the ω-3:ω-6 of membrane phospholipids (Gallai et al., 
1993; McCann et al., 2000).  However, many studies have noted increases in arachidonic 
acid (20:4) levels following supplementation through fish oil or flaxseed oil, which 
increases PGE2 production.  Therefore, it is desirable to find a way to supplement fatty 
acids in a manner that mitigates inflammation without increasing 20:4 levels. 
Conjugated linoleic acid (CLA) is an 18-carbon fatty acid with 2 double bonds in 
a conjugated system.  It originally generated interest for its anti-carcinogenic properties 
and has since been studied extensively in pigs.  It has been found to enter circulating 
levels in plasma and incorporate into muscle tissue following dietary supplementation in 
pigs (Kramer et al., 1998).  Recently, it has been discovered that CLA may have anti-
inflammatory properties, and following in vitro treatment to macrophages, was found to 
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reduce cytokine production following an inflammatory insult (Yang and Cook, 2003).  
When cytokines are produced during an inflammatory response, they signal neighboring 
cells to produce other inflammatory products including eicosanoids.  In a study 
supplementing CLA to pigs, Changhua et al. (2005) found a reduction in eicosanoid 
production.   
Currently, only one study has been performed in which horses were 
supplemented CLA.  The supplemented CLA reached measureable circulating levels in 
equine plasma after 14 d, and reached maximum concentrations 28 d following the onset 
of supplementation (Headley et al., 2011).  With this understanding, further investigation 
into the effects of CLA supplementation in the horse could provide essential information 
into its anti-inflammatory effects and ability to mediate cartilage degradation. 
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CHAPTER II 
 
REVIEW OF THE LITERATURE 
 
Introduction 
 Lameness in horses is described as an abnormality of gait, such that a horse 
cannot be used for its intended purpose (McIlwraith et al., 2012).  In Thoroughbred 
racehorses, lameness is the primary factor in loss of use and delayed race starts 
(Rossdale et al., 1985).  Osteoarthritis, a common joint disease in humans, is the leading 
cause of lameness in the equine industry, and is believed to contribute to approximately 
60% of lameness in the horse (McIlwraith et al., 2012).  The pathophysiology of OA in 
humans and horses is very similar, making horses an ideal model for research, which 
may be beneficial to both the equine industry and human medicine.   
The definition of OA is the degeneration of articular cartilage, but it also affects 
the underlying bone and soft tissues (Sandell and Aigner, 2001).  When a healthy joint 
undergoes repeated trauma or overloading, excessive inflammatory responses can lead to 
changes in articular cartilage metabolism.  Articular cartilage damage can be classified 
as primary or secondary, with primary cartilage damage being caused by abnormal 
loading to healthy cartilage (McIlwraith et al., 2012).  Secondary cartilage damage 
occurs because of damage to another area of the synovial joint.  For example, damage to 
the subchondral bone can lead to articular cartilage damage as a secondary response 
(McIlwraith et al., 2012).   
 Currently, diagnostic techniques for equine OA are limited to imaging, such as 
radiography, ultrasound, or MRI.  These techniques are often not used until there are 
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clinical signs of OA, including lameness, heat, swelling, pain on flexion and decreased 
range of motion (Jansson, 1996).  It has become widely accepted that radiographic 
imaging techniques often do not pick up early degeneration of articular cartilage.  It is 
desirable to find a diagnosing technique that can detect the early metabolic changes 
within a joint capsule.  The investigation of synovial fluid biomarkers as indicators of 
bone, cartilage and soft tissue health is a growing area of research and can provide 
information about joint health prior to visual radiographic changes.   
 Once clinical signs of OA appear, there are multiple therapeutic methods 
available; however, there is very little research to support preventative measures.  
Preventative treatments to reduce inflammation prior to changes in articular cartilage 
need to be investigated due to the small success of treatments of existing OA.  Existing 
therapies to treat OA do not reverse the damage to articular cartilage, but manage 
symptoms and could limit further inflammation from continuing the deleterious effects 
on articular cartilage (Jansson, 1996).  Following the onset of clinical symptoms, the 
most common treatments include non-steroidal anti-inflammatory drugs (NSAIDs), 
intra-articular corticosteroids, and PSGAGs (Trotter and McIlwraith, 1996).  A more 
recent area of research is evaluating gene therapy as a possible treatment for OA to 
alleviate pain and preserve articular cartilage (Frisbie et al., 2002).   
 The therapies described above are utilized once clinical symptoms have initiated.  
Therefore, it is desirable to find preventative measures to delay the onset of 
osteoarthritic changes in the joints of humans and horses.   Glucosamine, an amino 
sugar, has been researched as a possible dietary supplement to mitigate changes in 
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markers of inflammation and cartilage metabolism in young horses (Lucia, 2013).  
Others have studied dietary supplementation of polyunsaturated fatty acids (PUFAs), 
such as ω-3s, as anti-inflammatories in horses and humans (Gallai et al., 1993; Lucia et 
al., 2009).  Recently, however, researchers have begun to test the effects of CLA on 
inflammation through in vitro and in vivo studies (Yang and Cook, 2003; Changhua et 
al., 2005). 
 Conjugated linoleic acid describes a group of fatty acid isomers containing 18 
carbons with two double bonds in a conjugated orientation.  There are 28 CLA isomers, 
the most common of which are cis-9, trans-11 and trans-10, cis-12 (c9, t11; t10, c12; 
Bhattacharya et al., 2006).  Both isomers are naturally occurring in beef and dairy 
products (Hur and Park, 2007).  While CLA has been studied in mice, swine and human 
subjects to evaluate anti-inflammatory, anti-carcinogenic, anti-adipogenic, anti-
arthrogenic and anti-diabetogenic properties, only one study has evaluated effects of 
CLA supplementation in horses (Bhattacharya et al., 2006; Headley et al., 2011).  The 
anti-inflammatory properties of CLA are of greatest interest as a preventative strategy 
for OA in performance horses.  
Synovial Joint Anatomy and Physiology 
 Synovial joints, also known as diarthrodial joints, in all species function to 
facilitate motion and transfer load (Todhunter, 1996).   They are composed of 
subchondral bone, articular cartilage and a joint capsule, which are supported by 
collateral ligaments (van Weeren and de Grauw, 2010; Todhunter, 1996).  The joint 
capsule is made up of two major components: the fibrous portion and inner synovium.  
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The fibrous portion of the joint capsule is made up of collagen fibers to provide 
structural support for the joint capsule.  The synovium, sometimes referred to as the 
synovial membrane, is located just inside the fibrous portion of the joint capsule and is 
highly vascularized and innervated (Todhunter, 1996).  During movement, the synovium 
is able to simultaneously contract and distend as the horse extends and flexes to ensure 
adequate lubrication across the joint to protect articular cartilage and subchondral bone 
(Caola, 2003).  
Synoviocytes are cells that make up the synovium, and are responsible for the 
exchange of compounds from blood to synovial fluid via an ultrafiltrate system (van 
Weeren and de Grauw, 2010).  The production of hyaluronan, a non-sulfated 
glucosaminoglycan, is a significant role of synoviocytes.  Following production, 
hyaluronan is secreted into synovial fluid and provides its viscous nature for lubrication 
of articular cartilage (Todhunter, 1996).  Further, these cells play a significant role in the 
inflammatory response to trauma and the onset of OA.  
Synovial fluid is located within the joint capsule, beneath the synovium, and 
functions to lubricate the joint system and provide essential nourishment to articular 
cartilage and intra-articular ligaments (Todhunter, 1996).  Articular cartilage lies on the 
articulating surface of subchondral bone to provide protection to the boney processes 
and allow for smooth movement during motion.  Made up of approximately 70% water, 
articular cartilage is translucent in appearance, and is composed of chondrocytes and an 
extracellular matrix (Neil et al., 2005).  During loading, articular cartilage self-
compresses, releasing its water contents into the synovial fluid cavity.  When the load is 
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removed, cartilage acts as a sponge and rehydrates (Caola, 2003).  During rehydration 
through unloading, articular cartilage is able to uptake essential nutrients from the 
synovial fluid, thereby maintaining its integrity (Caola, 2003). For this reason, 
movement is essential to sustain joint health; however, during excessive loading, this is 
also where articular cartilage uptakes degradative enzymes produced by synoviocytes.   
The extracellular matrix of articular cartilage is made up of collagen, 
proteoglycans and glycoproteins, which make up approximately 50, 35 and 10% of 
articular cartilage on a dry weight basis, respectively (Todhunter, 1996).  Type II 
collagen constitutes the fibrous portion of the extracellular matrix and is responsible for 
tensile strength of articular cartilage (Neil et al, 2005).  The other major solid component 
of articular cartilage is proteoglycan.  Proteoglycans are glycosylated proteins, whose 
function is dependent upon the glycosaminoglycans present (Yanagishita, 1993).  In 
general, they function to provide hydration and swelling pressure to articular cartilage, 
which allows the joint to withstand compression forces (Yanagishita, 1993).  Aggrecan 
is the largest, most abundant and most extensively studied proteoglycan within articular 
cartilage.  It is produced by chondrocytes and is made up of covalently attaching 
glycosaminoglycans chondroitin sulfate and keratin sulfate to the proteoglycan protein 
core (Neil et al., 2005; Todhunter, 1996).  A comprehensive picture of synovial joint and 
extracellular matrix anatomy is provided in Fig. 1.   
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Figure 1: Synovial joint anatomy with articular cartilage composition (adapted from 
Neil et al., 2005). 
 
 
While the extracellular matrix provides structure for articular cartilage, 
chondrocytes play a major role in the homogeneity of articular cartilage.  Chondrocytes 
are the cellular component of articular cartilage and amount to approximately 1 to 12% 
of total dry matter (Todhunter, 1996).  They obtain nutrients from synovial fluid, which 
include glucose, oxygen and amino acids that diffuse into the synovial fluid from the 
vasculature in the synovium via the ultrafiltrate system described previously.  As a 
general rule, any molecule smaller than hemoglobin can diffuse into the extracellular 
matrix and to chondrocytes (Todhunter, 1996).  Some of the glucose taken up by the 
chondrocytes is converted to glucosaminoglycans (GAGs), and later covalently bound to 
a protein core for proteoglycan production to maintain the integrity of the extracellular 
matrix (Fig. 2 Neil et al., 2005).   Furthermore, chondrocytes produce type II collagen; 
however, the complex processes and multiple cellular compartments involved in its 
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production cause its turnover rate to be longer than that of proteoglycans.  For example, 
it is estimated that the average type II collagen turnover times in dogs and humans is 120 
and 350 years, respectively (Todhunter, 1996). Due to this slow turnover it is important 
to maintain the integrity of the collagen portion of the extracellular matrix to maintain 
joint health and stability.   
 
 
 
Figure 2: Production of glucosaminoglycans keratin sulfate, dermatan sulfate and 
chondroitin sulfate from glucose. (Adapted from Neil et al., 2005). 
 
 
Finally, subchondral bone is the innermost component of the synovial joint 
system and provides the structural support for the animal.  The subchondral bone can be 
subdivided into the subchondral bone plate and trabecular bone, which separates 
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calcified cartilage from marrow-containing spaces of bone (Kawcak et al., 2001).  The 
trabecular bone contains blood vessels that channel into the calcified cartilage layer and 
provide nourishment to deeper portions of articular cartilage that cannot receive nutrients 
from the synovial fluid (Duncan et al., 1987).  Subchondral bone is extensively 
adaptable and undergoes modeling and remodeling as a response to loading.  Modeling 
is described as solely bone deposition, while remodeling indicates the removal and 
replacement of bone tissue.  Osteocytes regulate the modeling and remodeling of 
subchondral bone and can sense local changes in loading intensities and duration 
(Duncan and Hruska, 1994).  As with articular cartilage, regular exercise is 
advantageous for the maintenance and strengthening of subchondral bone.  Bone 
formation tends to slow when loading duration or intensity decreases.  For example, 
when Thoroughbred foals were moved from pasture to stable housing, there was a 
reduction in bone formation due to decreased physical activity (Maenpaa et al., 1988).  
When assessing subchondral bone, it is normal for different areas to have varying 
densities and thickness due to variations in mechanical processes across the joint 
(Kawcak et al., 2001).   
In growing animals, modeling of bone should exceed bone resorption for normal 
skeletal development.  The modeling of bone is due to the presence of peptide growth 
factors such as: TGF-β, IGFs, platelet-derived growth factor and fibroblast growth factor 
(Todhunter, 1996).  These growth factors affect cellular proliferation, which gives rise to 
increased calcification.  However, during excess loading or trauma, all cells within the 
 12 
 
 
synovial joint are able to produce cytokines and eicosanoids, which prompt tissue 
degradation and lead to joint disease. 
Pathophysiology of Inflammation and Osteoarthritis 
 A degenerative joint disease, OA, is characterized by degradation of articular 
cartilage, and can encompass changes to subchondral bone as well.  Simply put, OA is 
caused by abnormal loading on normal cartilage or normal loading on abnormal cartilage 
(McIlwraith et al., 2012).  Recurring or severe acute synovitis has also been identified as 
a precursor to equine OA, and can account for the inaugural changes in articular 
cartilage.  Each cell type within the synovial joint has the capacity to initiate an 
inflammatory response.  Regular exercise and movement is encouraged to maintain the 
health and homogeneity of the synovial joint; however, too much can shift joint 
metabolism from anabolic to catabolic, leading to a net degeneration of joint tissue.  
Inflammation 
 The inflammatory response occurs following excess loading or trauma to the 
joint.  The purpose of an inflammatory response is to protect against foreign agents and 
remove damaged tissues.  With the occurrence of trauma, cells are damaged and the 
inflammatory response is initiated to destroy and remove the damaged cells to protect 
remaining healthy cells from secondary damage.  Inflammation within the synovial joint 
can occur individually in the synovial membrane, articular cartilage or subchondral 
bone, or in combination; however, the responses vary between tissues due to vasculature 
(McIlwraith, 1996).   
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When inflammation occurs in the synovial membrane, it is referred to as 
synovitis.  Synoviocytes play a major role in initiating the inflammatory response; 
however, following trauma, neutrophils, macrophages and lymphocytes are recruited to 
the site to assist in degradation and removal of damaged cells (Jansson, 1996; 
McIlwraith et al., 2012).  The macrophages and neutrophils produce the primary 
inflammatory cytokines including IL-1 and TNFα.  Equine IL-1 was purified from 
monocytes following the use of lipopolysaccharide (LPS) to induce an inflammatory 
response confirming their origin from leukocytes recruited to a site of inflammation 
(May et al., 1990).  Cytokines TNFα and IL-1 perform similar functions within the joint.  
Both inhibit the production of proteoglycans in articular cartilage and initiate a response 
by synoviocytes and chondrocytes (Arner and Pratta, 1989).  In an in vitro study 
performed using bovine and human articular cartilage slices, it was found that TNFα 
both degrades and inhibits the synthesis of proteoglycans (Kowanko et al., 1990).   
Chondrocytes and synoviocytes respond to trauma directly, but also respond to 
cytokines IL-1 and TNFα as a secondary up-regulation.  In response to injury and 
presence of cytokines, synoviocytes release aggrecanase, MMPs, free radicals and 
prostaglandins (McIlwraith et al., 2012).  Each product is released into the synovial fluid 
and can be absorbed by the articular cartilage where chondrocytes become exposed to 
IL-1 and TNFα, and exhibit their own inflammatory response (Jansson, 1996).  This 
evidence suggests that the inflammatory response extends into the synovial fluid and 
articular cartilage whether the injury affects those areas or not. 
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The MMPs released by synoviocytes and chondrocytes include stromelysin, 
collagenase and gelatinase enzymes (McIlwraith et al., 2012).  They are characterized as 
such because of their requirement for Zn
2+
 in their active sites (McIlwraith, 1996).  
These enzymes collectively contribute to degradation of the extracellular matrix of 
articular cartilage.  In healthy articular cartilage, there is a balance between MMPs and 
tissue inhibitor of metalloproteinases to maintain the extracellular matrix; however, 
following trauma, this balance is disturbed, leading to degradation of type II collagen 
and proteoglycan turnover (Palmer and Bertone, 1994).   The MMP stromelysin is 
believed to cleave proteoglycans such that the glycosaminoglycan-bearing region is 
released (Fosang et al., 1991).  Stromelysin is also capable of denaturing collagen, as 
well as activating the zymogen procollagenase to collagenase for further fiber 
degradation (Fig. 3; Murphy et al., 1987).   
When a type II collagen fibril is exposed to MMPs such as collagenase, hidden 
epitopes within the collagen fiber become exposed (Trumble et al., 2009).  The exposed 
epitopes can then be used as biomarkers to indicate metabolism of type II collagen at the 
time of collection.  Recent research has focused on the use of these hidden epitopes to 
diagnose early changes in articular cartilage indicative of OA before radiographic 
changes become evident.  The most reliable source of measurement of such epitopes is 
through synovial fluid samples, which provide the most direct assessment of type II 
collagen metabolism.  One such biomarker is C2C, which has been used frequently in 
equine research as a biomarker of collagen metabolism.  
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Figure 3: Collagenase degradation of type II collagen (adapted from Poole, 1992). 
 
 
In addition to the MMPs, eicosanoids, including prostaglandins, are released 
from synoviocytes and chondrocytes.  The most significant prostaglandin in the 
inflammatory response is PGE2.  It is synthesized from 20:4 via the cyclooxygenase-2 
(COX-2) pathway (Fig. 4; Vane et al., 1998).  The COX enzyme is located on 
macrophages released during an inflammatory response (Iwakiri et al., 2002). While 
20:4 is present in all cell membranes, repetitive trauma increases 20:4 concentrations 
within the membranes of chondrocytes (Chrisman et al., 1981).  The functions of PGE2 
include vasodilation, enhancement of pain perception, proteoglycan depletion and bone 
demineralization (McIlwraith, 1996).  The enhancement of pain perception is a 
suggested correlation with substance P, which is a neurotransmitter present in the joint 
capsule (Kirker-Head et al., 2000). 
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Prolonged or repeated exposure to inflammatory cytokines and eicosanoids can 
damage articular cartilage beyond the capacity of regeneration.  When this occurs, OA is 
the unfortunate development.  Deterioration in the integrity of articular cartilage affects 
the health and strength of subchondral bone.  If inflammation can be abated, the onset of 
OA can be delayed.  Therefore, it is desirable to seek ways in which to limit the release 
of inflammatory cytokines and eicosanoids as an approach to mitigating cartilage 
degradation.   
 
 
 
Figure 4: Synthesis of PGE2 from 20:4 (adapted from Vane et al., 1998) 
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Effects on Subchondral Bone 
Damage to subchondral bone can occur after the integrity of articular cartilage is 
compromised, or changes in subchondral bone can lead to changes in articular cartilage 
leading to OA.  For this reason, researchers often induce OA by creating an 
osteochondral fragment in the subchondral bone of a synovial joint (McIlwraith et al., 
2012).  Through this process, pathogenesis of OA can be monitored at various stages 
without creating significant pain.   
Like articular cartilage, bone is constantly turning over.  In growing animals, 
bone formation should exceed bone resorption, and in adults, formation and resorption 
should be balanced.  However, when this balance is obscured, net bone loss or excess 
calcification occurs, which can damage articular cartilage.  The two primary cell types 
associated with bone formation and resorption are osteoblasts and osteoclasts, 
respectively (Harada and Rodan, 2003).  When mechanical loads are increased, bone 
formation is stimulated and bone resorption is suppressed.  During bone formation, 
osteoblasts synthesize bone alkaline phosphatase, which likely contributes to the 
calcification of bone matrix (Trumble et al., 2007).   
When articular cartilage is damaged, the response of subchondral bone is usually 
microdamange (Kawcak et al., 2001).  The microdamage can lead to an inflammatory 
response being initiated by cells within subchondral bone.  It has been suggested that the 
eicosanoid, PGE2 that is also associated with synovitis, can cause bone demineralization 
(Raisz, 1995; Schlueter and Orth, 2004).  It is likely that inhibiting bone resorption will 
also inhibit prostaglandin release during OA (Kawaguchi et al., 1994).   
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Use of Inflammatory and Cartilage Biomarkers  
 Currently, diagnosis of OA is performed through the use of radiography to 
evaluate thinning of articular cartilage.  Since a major precursor to OA is inflammation, 
the diagnosis of acute or recurring inflammation is desirable for the prevention or delay 
of OA onset.  A popular area of research has been investigating biomarkers and their 
correlation with the inflammatory response and degradation of articular cartilage.  Early 
research in biomarkers began with urinary analysis, as it is a less invasive means by 
which to collect a sample.  More recently, however, blood has become a popular means 
to analyze inflammation, but synovial fluid biomarkers will give the most direct 
assessment of the status of the synovial joint. 
 Prior to biomarker analysis, hormones were analyzed as indicators of joint 
health; however, they can be unreliable.  Early urinary analysis investigated bone 
resorption through markers released into circulation and excreted through urine.  Two 
such markers include pyridinoline and deoxypyridinoline, which provide information on 
ongoing bone resorption in disorders such as osteoporosis, hyperparathyroidism and 
metastatic bone disease (Seibel et al., 1992).  Urinary markers were soon after replaced 
with blood and synovial fluid markers.  The majority of the biomarkers analyzed through 
blood and synovial fluid are the same; however, there is no way of knowing that the 
biomarkers present in blood in fact originated in the joint of interest.   
Markers of Inflammation 
   Markers of inflammation are the same as the inflammatory response markers 
described previously; however, cartilage and bone biomarkers are representative of 
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products released during degradation.  Many studies have researched the presence of 
synovial fluid cytokines and eicosanoids present with inflammation (Bertone et al., 
2001; De Grauw et al., 2006; Frisbie et al., 2008).  Products such as TNFα, IL-1 and 
PGE2 are the most extensively studied of the inflammatory biomarkers.  Inflammatory 
markers PGE2, IL-1 and TNFα were analyzed in a study performed using horses with 
naturally occurring joint disease (Bertone et al., 2001).  PGE2 concentrations had the 
greatest correlation to joint disease, and was determined to be a significant indicator of 
any joint disease at varying levels of severity with values greater than 63.5 pg/mL 
(Bertone et al., 2001).  However, in this study, IL-1 concentrations varied considerably 
with individual horses making it a poor indicator of joint disease severity (Bertone et al., 
2001). When OA was experimentally induced via an osteochondral fragment, PGE2 was 
found to peak approximately 7 d following surgical OA induction (Frisbie et al., 2008).  
However, other studies have used LPS to induce a local inflammatory response in the 
joint.  When this method was used, PGE2 concentrations peaked between 8 and 12 h 
following LPS injection (de Grauw et al., 2009; Lucia et al., 2013).  It is important to 
note, however, that when synovial fluid samples are repeatedly collected via 
arthrocentesis, the invasive procedure further stimulates inflammation and could lead to 
confounding effects when evaluating inflammation (van den Boom et al., 2005).   
Markers of Articular Cartilage 
 When evaluating biomarkers as an indication of articular cartilage health, 
inflammatory markers do not provide any indication of the current cartilage metabolism.  
Therefore, several other markers have been used to provide indications of cartilage 
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remodeling or degradation. The biomarkers produced by articular cartilage enter the 
synovial fluid and concentrations can be analyzed without taking articular cartilage 
samples, providing a less invasive technique to study articular cartilage metabolism.  It 
has been suggested that changes in GAG concentration throughout the extracellular 
matrix is an indication of matrix breakdown; therefore, the GAG content of synovial 
fluid can be assessed for articular cartilage metabolism (McIlwraith et al., 2012).   The 
GAG content of articular cartilage increased following induction of OA by 
osteochondral fragmentation, indicating that it could be a possible indicator of OA 
(Frisbie et al., 2008).  However, in a study performed in horses with naturally occurring 
lameness, no correlation was seen between GAG content and articular cartilage 
degradation; therefore, GAG content may not be the best indicator of articular cartilage 
degradation (Fuller et al., 2001).   
 Matrix MMPs have also been considered as possible markers to indicate 
proteoglycan degradation of the extracellular matrix; however, in a study of young 
horses with evidence of osteochondrosis, matrix MMP concentrations were unreliable as 
a possible marker (de Grauw et al., 2011).  One marker that has proven reliable to 
evaluate proteoglycan stability is chondroitin sulfate 846 (CS846).  Presence of CS846 
indicates regeneration of proteoglycan content in articular cartilage.  In all studies 
analyzed, CS846 proved to be a reliable marker of articular cartilage regeneration 
(Frisbie et al., 2008; de Grauw et al., 2011; de Grauw et al., 2009).  In a study using 
osteochondral fragmentation to initiate osteochondrosis, CS846 concentrations in 
synovial fluid increased after 7 d and peaked 42 d after fragmentation (Frisbie et al., 
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2008).  In naturally occurring osteochondrosis, CS846 was greater in horses with 
osteochondrosis than horses with normal joints (de Grauw et al., 2011).  Thirdly, in a 
study using intra-articular LPS injection to induce an inflammatory response, CS846 
peaked approximately 24 h post-injection and returned to normal values 168 h post-
injection (de Grauw et al., 2009).  The combined analysis of these studies indicate that 
CS846 is a reliable marker of proteoglycan regeneration in naturally occurring 
osteochondrosis, osteochondral fragmentation and LPS models, but provides no 
information on the metabolism of type II collagen, which is the structural component of 
articular cartilage..   
 There are two contrasting markers of type II collagen turnover that have been 
studied extensively and have correlations with extracellular matrix metabolism.  
Carboxypeptide of type II collagen is an indicator of collagen regeneration.  Billinghurst 
et al. (2003) evaluated foals separated into three treatment groups: stalled, exercised and 
stalled, and pasture housed.  Serum CPII was greatest in foals housed in pasture (522.4 ± 
35.8 ng/mL), and lowest in animals undergoing forced exercise (387.8 ± 26.2 ng/mL; 
Billinghurst et al., 2003).  In a second study, CPII was evaluated following an 
inflammatory response initiated via intra-articular LPS injection and concentrations in 
synovial fluid peaked 24 h post-injection (Lucia et al., 2013).  When OA was induced by 
creating an osteochondral fragment, CPII concentrations in synovial fluid increased 
approximately 21 d following surgery (Frisbie et al., 2008).  These studies indicate that 
following loading or inflammation, type II collagen aims to repair and regenerate itself; 
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however, as stated previously, the turnover rate of type II collagen is extremely slow 
(Billinghurst et al., 2003; Frisbie et al., 2008; Lucia et al., 2013).   
 The second marker of type II collagen turnover, C2C, is a marker of type II 
collagen degradation.  It is found in synovial fluid when a collagen fiber becomes 
exposed to collagenase. When the collagen fiber begins to denature, the C2C epitope is 
exposed and released into synovial fluid where it can then be measured.  Several studies 
have used both C2C and CPII as contrasting markers of cartilage metabolism.  One such 
study, following intra-articular LPS injection, measured concentrations of synovial fluid 
C2C, and observed peak values at 24 h post-injection, similar to CPII, with values of 
344.97 ± 23.34 ng/mL (Lucia et al., 2013).  Lucia et al. (2013) also indicated that C2C 
concentrations increase with increasing levels of inflammation through the use of three 
levels of LPS, further confirming the efficacy of C2C as a measurement of cartilage 
metabolism.  Billinghurst et al. (2003) found elevated values in foals undergoing 
extensive training (1933.4 ± 598.6 ng/mL) and lower values in horses housed on pasture 
(906.5 ± 242.6 ng/mL) indicating increased loading to joints can promote cartilage 
degradation.  These studies also found a correlation between the two type II collagen 
biomarkers.  When type II collagen degradation increases via C2C measurements, 
regeneration also increases as measured through CPII.   
 All described biomarkers have been used to measure magnitudes of inflammation 
and cartilage metabolism with PGE2 being a reliable marker of joint inflammation, and 
C2C and CPII contributing to type II collagen.  More recent research has used these 
markers to determine efficacy of treatments and mitigation techniques.  By reducing 
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concentrations of inflammatory markers, including PGE2, cartilage degradation can be 
tempered to delay the onset of OA.  Among these mitigation techniques, diet is the most 
popular due to ease of administration.   
Polyunsaturated Fatty Acid Supplementation 
 Dietary supplementation of PUFAs, including ω-3 and ω-6, regulate 
inflammatory mediators including proinflammatory cytokines, anti-inflammatory 
cytokines, eicosanoids and nitric oxide (Bhattacharya et al., 2006).  Linoleic acid, an ω-6 
fatty acid, and α-linolenic acid (ALA), an ω-3 fatty acid, are essential fatty acids 
required in the diet of horses.  Monogastrics are unable to synthesize linoleic and ALA 
because of the lack of necessary desaturases to place the double bonds appropriately.  
Once the two essential fatty acids are supplemented, available desaturases and elongases 
can act to produce other fatty acids including 20:4, eicosopentanoic acid (EPA), and 
docosohexanoic acid (DHA).  In equine nutrition research, both EPA and DHA are 
commonly supplemented ω-3 fatty acids, and are believed to have anti-inflammatory 
effects, particularly EPA. The most common means of supplementation of EPA and 
DHA is fish oil; however, flaxseed oil is commonly used to supplement ALA, which can 
be converted to EPA and DHA (Hansen et al., 2002).   
 Dietary supplementation requires an adaptation period to the new product, which 
allows time for the added fatty acids to achieve circulating levels in plasma and 
incorporate into tissue (cellular) lipid membranes.  Following flaxseed oil 
supplementation, plasma concentrations of ALA were greater compared to horses 
receiving a control diet.  Because ALA is the precursor to EPA and DHA, both of these 
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isomers were also higher in plasma after 28 d compared to non-supplemented horses 
(Hansen et al., 2002).  Fish oil, on the other hand, is a direct source of both EPA and 
DHA, and after supplementation, both fatty acids reached peak circulating levels in 
equine plasma by the first collection period at 6 weeks following the onset of 
supplementation (Hall et al., 2004).  Protected fatty acids are meant to remain intact 
through the digestive process.  After feeding protected fatty acids to horses, EPA and 
DHA were maximized in plasma after 17 d (King et al., 2008).  These studies lend 
confidence that supplemented fatty acids can reach circulating levels in plasma by 28 d 
following the onset of supplementation. 
 It has been suggested that supplementation of products such as fish oil with EPA 
and DHA decreases cytokine (IL-1 and TNFα) production by macrophages during an 
inflammatory response (Calder, 1996).  Whether humans consumed fish oil for 6 or 24 
weeks, there was a notable decrease in IL-1 and TNFα concentrations (Gallai et al., 
1993; Endres et al, 1993).  Since IL-1 and TNFα stimulate synoviocytes and 
chondrocytes to produce eicosanoids and MMPs, the reduction in cytokine production is 
likely to reduce the overall inflammatory response.  By reducing exposure of articular 
cartilage to products of inflammation, the integrity of articular cartilage can likely be 
sustained without damage for an extended period.  
As well as reducing cytokine production, ω-3 supplementation can also shift the 
ω-3:ω-6 in cell membranes (McCann et al., 2000).  The ω-6 fatty acids are precursors to 
20:4, which produces the prostaglandins associated with inflammation.  By lowering the 
ω-6 concentration of membrane phospholipids, precursors to PGE2 production are 
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restricted, which can further reduce the inflammatory response following trauma.  For 
example, chicks fed a diet higher in ω-3 than ω-6 fatty acids had lower concentrations of 
20:4 in bone (Watkins et al., 1997).  It is important to note that, although fish oil is the 
most common means of EPA and DHA supplementation and has been found to reduce 
cytokine and eicosanoid production, it also contains a significant level of 20:4, which is 
the ω-6 precursor to PGE2.  For example, corn oil supplemented to horses contained 
undetectable levels of 20:4 and was used as the control diet; however, the fish oil 
supplemented contained 6.7% 20:4 (Hall et al., 2004).   The data suggests that fatty acid 
supplementation can mitigate the inflammatory response to possibly delay the onset of 
OA; however, a fat supplement low in 20:4 may be necessary to maximize anti-
inflammatory properties.  
Conjugated Linoleic Acid Supplementation 
 CLA was originally extracted in 1985 from ground beef and found to have anti-
carcinogenic effects.  It has since been heavily researched in areas of bone remodeling, 
attenuation of inflammation, and effects on body composition in multiple species (Pariza 
and Hargraves; Bhattacharya et al., 2006).  Most commonly, CLA has been 
supplemented as a top-dressed oil.  Supplemental forms of CLA contain predominantly 
c9,t11 and t10,c12 isomers, which are the primary isomers of focus in research as they 
are believed to be attributed to the majority of health benefits (Hur and Park, 2007; 
Bhattacharya et al., 2006).  Because these isomers are generally supplemented in 
combination, they do have independent, additive and antagonistic effects (Park and 
Pariza, 2007).  
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CLA and Body Composition 
The t10,c12 isomer is most closely associated with changes in body composition 
and reduction in body fat (Park et al., 1999).  This isomer is able to reduce body fat by 
inhibiting stearoyl-CoA desaturase, also known as the delta-9 desaturase, which is 
responsible for adding a double bond at the 9-carbon of a fatty acid chain (Hur and Park, 
2007).  The t10,c12 isomer is also capable of reducing hepatic release of apolipoprotein 
B, which is an integral part in the transport of triacylglycerols to tissues for storage in the 
body (Storkson et al., 2005).  Currently, there is only one study to determine the effects 
of CLA on body fat in the horse.  When fed a mixed isomer CLA supplement containing 
28.5% c9,t11 and 28.1% t10,c12 over a 6-wk period, horses showed no changes in body 
fat composition (Headley et al., 2011).  
CLA and Inflammation 
 More recently, research has shifted to investigate the anti-inflammatory effects of 
CLA.  The majority of research studies utilizing CLA have fed mixed isomers rather 
than single isomers.  Therefore, it is difficult to determine the effect of each isomer on 
inflammation and bone remodeling, however, it has been suggested that the c9,t11 
isomer is likely the primary contributor.  As described previously, macrophages and 
other white blood cells are sent to the location of injury and initiate an inflammatory 
response via the release of cytokines.  When CLA is supplemented and circulating in 
blood plasma, it has an affect on macrophage function as it reaches the site of trauma 
(Yang and Cook, 2003).   
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Following in vitro LPS injection into macrophages treated with CLA, TNFα 
concentrations were lower in macrophages receiving CLA than control cells (Yang and 
Cook, 2003).  A similar study aimed to determine the COX-2 activity with CLA 
supplementation in which macrophages were activated using LPS (Iwakiri et al., 2002).  
Those cells treated with CLA had 78% lower PGE2 production than cells maintained in a 
lipid-free medium (Iwakiri et al., 2002).  It has been hypothesized that depression in 
PGE2 production may be due to the suppression of the transcription of COX-2 (Iwakiri 
et al., 2002).  An alternative anti-inflammatory mechanism of CLA is perhaps a 
reduction in the activity of phospholipase A2.  This enzyme functions to cleave fatty 
acids off of the second position of the glycerol backbone.  By limiting the enzyme’s 
activity, the availability of 20:4 for the COX-2 pathway is reduced; therefore, lower 
concentrations of PGE2 would be expected following an inflammatory response (Eder et 
al., 2003).  Eder et al. (2003) confirmed CLA’s ability to lower the activity of 
phospholipase A2 through the use of human aortic endothelial cells.  
Changhua et al. (2005) performed an in vivo study using pigs challenged with 
LPS at 14 and 21 d following the onset of dietary supplementation of CLA at a level 
equal to 2% of the diet.  On d 21, concentrations of IL-1 were 61.2 and 94.8 ng/L for 
CLA and control pigs, respectively (Changhua et al., 2005).  Similarly, PGE2 
concentrations on d 21 were 703.4 and 998.7 pg/mL in pigs receiving CLA vs. control, 
respectively (Changhua et al., 2005).  The previous in vitro studies validated CLA’s use 
as an anti-inflammatory; however, the data presented by Changhua et al. (2005) 
confirms that CLA can be reach circulating levels through dietary supplementation and 
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function to reduce eicosanoid production.  The flow chart illustrated in Fig. 5 
summarizes these anti-inflammatory properties of CLA and how they act to delay the 
onset of OA. 
 
 
 
Figure 5: Mechanism of CLA effects on inflammation to prevent osteoarthritis (adapted 
from Hur and Park, 2007).  
 
 
CLA and Bone Metabolism 
 With these data regarding the effects of CLA on inflammation, questions have 
arisen about its effects on bone metabolism.  At this time, data to support CLA’s effects 
on bone metabolism are variable and few conclusions can be made; however, it is still 
 29 
 
 
hypothesized that CLA supplementation can have a positive effect on bone.  Osteoblasts, 
cells within bone responsible for resorption, produce PGE2 that initiates bone loss (Hur 
and Park, 2007).  As described previously, fatty acid supplementation can reduce 20:4 
levels in cell membranes, but CLA-specific supplementation may also reduce the 
activity of COX-2 to reduce PGE2 production.  This provides the basis for the theory of 
CLA’s effects on bone metabolism; however, the current data are unreliable.  For 
example, Kelly et al. (2003) suggested that CLA supplementation increased Ca 
absorption from the small intestine; however, they saw no effect on biomarkers of bone 
formation or resorption.  Similar results were observed in a study performed in adult 
men where markers of bone formation and resorption were analyzed and showed no 
difference between CLA and placebo treatments (Doyle et al., 2005).  In ovariectomized 
rats, however, CLA supplementation at 5 and 10 g/kg diet significantly lowered PGE2 
production, providing some evidence that CLA may, in fact, reduce bone resorption 
(Kelly and Cashman, 2004).   
 The extensive variability of data on the effects of CLA supplementation on bone 
health and metabolism make it difficult to formulate significant conclusions.  
Measurements of articular cartilage through the use of biomarkers can provide valuable 
understanding of the effects of CLA.  As of yet, no studies have been performed to 
determine the effects of dietary CLA on markers of articular cartilage metabolism and 
could be a reliable means to better determine the effects of CLA on joint health.    
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Conclusion 
 In summary, OA is the leading cause of lameness in the equine industry 
(McIlwraith et al., 2012).  Its characterization as loss of articular cartilage makes it 
desirable to search for a solution to stop or reverse the degradation process.  When an 
animal undergoes overloading or trauma to a synovial joint, an inflammatory response is 
initiated.  The goal of the inflammatory response is to remove damaged cells; however, 
healthy cells and matrix tissues can become damaged in the process.  When 
inflammation occurs, white blood cells move to the location of trauma and release pro-
inflammatory cytokines such as IL-1 and TNFα.  The trauma and presence of the 
cytokines signal local cells such as synoviocytes or chondrocytes to release degradative 
enzymes, eicosanoids and free radicals.  Each of these products plays a role in the 
degradation of the extracellular matrix of articular cartilage. 
 The extracellular matrix is made up of type II collagen and proteoglycans, which 
provide its elastic properties.  Proteoglycans can undergo degradation and regeneration 
more rapidly than type II collagen; therefore, the loss of type II collagen is paramount in 
the occurrence of OA.  At this point, diagnosis of OA cannot be performed until 
significant changes in the integrity of articular cartilage can be seen through 
radiographic imaging.  The use of inflammatory biomarkers could lead to earlier 
diagnosis, and the ability to provide treatment before excess damage exists.   
 Mitigation of inflammation is likely the best way to delay the onset of OA.  The 
supplementation of PUFAs such as ALA, EPA and DHA has been successful in 
reducing the inflammatory response by reducing cytokine and eicosanoid production.  
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Fish oil is the most common means of supplementation of ω-3 fatty acids; however, it 
also has a significant level of 20:4 within the oil.  Since 20:4 is a direct precursor to 
prostaglandin production, it is desirable to find a way to maximize anti-inflammatory 
properties without also supplementing a pro-inflammatory.  The use of CLA-rich oil, 
which is often plant-derived and contains very little 20:4, could provide a better method 
by which to mitigate inflammation through dietary supplementation.   
 Therefore, the objective of this study was to determine the incorporation of 
supplemental CLA into circulating levels of plasma and to evaluate the effects of dietary 
CLA supplementation on joint inflammation following an LPS challenge.  This overall 
objective was tested in two phases with phase one used to determine the incorporation of 
supplemental CLA to circulating levels in plasma.  Phase two was then be used to 
evaluate the potential of dietary CLA to mitigate induced intra-articular inflammation 
and cartilage metabolism.  The long-term goal of this study is to determine the influence 
of diet on joint inflammation in young horses and its effect on joint health as an adult.   
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CHAPTER III 
MATERIALS AND METHODS 
 
All procedures and handling of horses was approved by the Texas A&M University 
Institutional Animal Care and Use Committee (AUP # 2011-170) 
Horses and Dietary Treatments 
Seventeen Quarter Horse yearlings (n = 8 males, n = 9 females) with average age 
of 470 ± 26 d and BW of 354.0 ± 16.0 kg were used in a randomized complete block 
design for a 56-d trail separated into two phases.  Phase 1 was used to determine 
incorporation of dietary CLA supplementation into plasma.  Phase 2 immediately 
followed phase 1, on d 42 of the study.  During phase 2, an intra-articular LPS challenge 
was conducted to induce a local, acute inflammatory response in the radiocarpal joint.  
Prior to the start of the experiment, horses were blocked by age, sex and BW and 
randomly assigned to one of three treatment groups.  Throughout the experiment, horses 
were housed in 3.0 m x 3.0 m box stalls from 1830 h to 0930 h daily.  Between 0930 h 
and 1830 h, horses were allowed free exercise in dry-lots, with the exception of d 42 
when the LPS challenge was conducted.   
 All diets were formulated to be isocaloric and isonitrogenous.  Horses were fed 
individually at 1% BW (as-fed) commercial concentrate feed (14% CP textured feed, 
Producers Cooperative Association, Bryan, TX) and 1% BW (as fed) coastal 
bermudagrass (cynodon dactylon) hay daily separated into two feedings at 0630 and 
1830 h.  All dietary treatments were top-dressed on the concentrate feed and fed as a 
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percent of total diet.  Horses received either a control diet containing 1% soybean oil 
(CON; n = 6), 0.5% soybean oil + 0.5% CLA (LOW; n = 5), or 1% CLA (HIGH; n = 6).   
The CLA supplement contained 55% CLA with a mixture of cis-9, trans-11; trans-10, 
cis-12; and trans-9, trans-11 isomers (Lutalin®, BASF Corp., Florham Park, NJ).  Days 0 
to 7 were used as a dietary adaptation period where horses were slowly adapted to 
concentrate from their previous diet to treatments by increasing treatment diet and 
decreasing the previous diet by 25% every 2 d until horses received only the treatment 
diet on d 7.  Oil supplementation began on d 1.  Starting on d 7, no significant refusals of 
diet or treatments were observed.  Samples of concentrate, hay, soybean oil and CLA 
were all analyzed by a commercial laboratory for nutrient content (Table 1) and fatty 
acid concentrations (Table 2). 
 
 
Table 1. Nutrient analysis of the commercial concentrate and coastal bermudagrass hay 
(cynodon dactylon). 
  Concentrate
a
 Coastal Bermudagrass Hay 
Dry Matter, % 92.35 92.45 
Crude Protein, % DM 18.82 11.26 
NDF, % DM 16.83 61.05 
ADF, % DM 9.47 33.87 
DE, Mcal/kg DM 3.42 2.51 
EE, % DM 6.84 3.53 
Ca, % DM 1.14 0.6 
P, % DM 0.73 0.22 
K, % DM 1.35 1.12 
Mg, % DM 0.26 0.34 
   
a
 14% CP textured feed (Producer’s Cooperative, Bryan, TX) 
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Table 2.  Concentration of CLA isomers and arachidonic acid in feedstuffs and 
supplements. 
Fatty Acid Concentrate
a
 
Coastal 
Bermudagrass Hay 
Soybean 
Oil
 
CLA
b
 
cis-9, trans-11 CLA, % ND
c 
ND ND 26.18 
trans-10, cis-12 CLA, % ND ND ND 26.12 
Arachidonic acid, % 0.25 0.52 0.32   0.57 
a
 14% CP textured feed (Producer’s Cooperative, Bryan, TX) 
b
 Lutalin® (BASF Corp., Florham Park, NJ) 
c
 ND, not detectable (minimum detectable level 0.003%) 
 
 
Sample Collection 
Phase 1 
 Weekly, beginning at d 0, physical growth measurements were recorded 
including BW, wither and hip heights, body length, heart girth circumference, rump fat 
thickness and body condition score (BCS).  The BCS was determined using the 1 to 9 
scale outlined by Henneke et al. (1983).  Rump fat thickness was measured via 
ultrasound images on the left hip at a point 5 cm dorsal of halfway between the first 
coccygeal vertebrae and the ischium (Westervelt et al., 1976) using an ultrasound 
instrument (Aloak SSD-500V, Aloka Inc., Tokyo, Japan).  Approximately 10 mL whole 
blood were collected weekly via jugular venipuncture into 10-mL evacuated tubes 
containing 0.1 mL 15% buffering solution and 15 mg K3 EDTA (BD Vacutainer, 
Franklin Lakes, NJ).  Samples were immediately placed on ice and centrifuged at 2,000 
x g for 20 min at 4°C.  Plasma was collected into pour-off tubes and stored at -20°C for 
subsequent analysis.   
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Phase 2 
 On d 41, prior to LPS challenge, radiocarpal joints were clipped to allow for ease 
of aseptic preparation before arthrocentesis.  On d 42, an LPS challenge was conducted.  
For each horse, radial carpal joints were randomly assigned as either treatment (LPS) or 
contralateral control (LRS).  At pre-injection h 0 (PIH 0), carpal joints were aseptically 
prepared and horses were sedated with 1.5 mL Sedivet
®
 (romifidine hydrochloride 1% 
injection, Boehringer Ingelheim, Fremont, CA).  Approximately 4 mL synovial fluid was 
collected via arthrocentesis by veterinarians from the Texas A&M University Large 
Animal Clinic (College Station, TX).  Immediately following PIH 0 sample collection, 
0.5 ng Escherichia coli O55:B5 derived lipopolysaccharide (LPS; Sigma-Aldrich, St. 
Louis, MO) was injected to the randomly assigned LPS joint.  The 0.5 ng LPS was 
reconstituted in 0.8 mL sterile lactated Ringer’s solution (LRS).  The LRS joint received 
0.8 mL sterile LRS only.  Injections were given at a location medial to the extensor carpi 
radialis tendon in the palpable depression between the radial carpal bone and the third 
carpal bone to a depth of approximately 12.7 mm to avoid unnecessary contact with 
articular cartilage (McIlwraith and Trotter, 1996).   
 Following LPS injection, synovial fluid samples were collected via arthrocentesis 
at 6, 12, 24, 168 and 336 h.  Synovial fluid samples were transferred to non-additive 10 
mL vacutainers (serum blood collection tubes, BD Vacutainer, Franklin Lakes, NJ) and 
immediately placed on ice.  Synovial fluid was then divided into small aliquots in 1.5 
mL snaplock microtubes and stored at -20°C for later analysis.  Prior to collection times 
PIH 0, and 6, 12 and 24 h post-injection, rectal temperature (RT; °C), heart rate (HR; 
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beats per min), and respiration rate (RR; breaths per min) were recorded.  Prior to each 
collection time, carpal circumference was measured at the level of the accessory carpal 
bone using a soft tape measure, and surface temperature of each carpal joint was 
determined at the same location and from a distance of 1.2 m using an infrared camera 
(FLIR E60 Series, Flir Systems Inc., Wilsonville, OR). 
Sample Analysis 
Nutrient Analysis 
 Hay and grain samples were dried for 48 h at 38°C (Lindberg/Blue M, Asheville, 
NC), then ground through a 1 mm mesh screen (Thomas Model 4 Wiley Mill, Thomas 
Scientific, Swedesboro, NJ) prior to analysis.  Fatty acids from hay, grain, soybean oil 
and CLA supplements was extracted and methylated using a modified Folch method and 
analyzed using a gas chromatograph (Folch et al., 1957; model CP-3800 fixed with a 
CP-8200 autosampler, Varian Inc., Walnut Creek, CA)).  Nutrient content was analyzed 
by a commercial laboratory (SDK Laboratories, Hutchinson, KS).  
Plasma Analysis 
 Total lipids were extracted by a modification of the method of Folch et al. 
(1957).  One mL of plasma was extracted in chloroform:methanol (2:1, v/v) and fatty 
acid methyl esters (FAME) were prepared as described by Morrison and Smith (1964), 
modified to include an additional saponification step (Archibeque et al., 2005). The 
FAME were analyzed using a Varian gas chromatograph (model CP-3800 fixed with a 
CP-8200 autosampler, Varian Inc., Walnut Creek, CA). Separation of FAME was 
accomplished on a fused silica capillary column CP-Sil88 [100 m × 0.25 mm (i.d.)] 
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(Chrompack Inc., Middleburg, The Netherlands), with hydrogen as the carrier gas (flow 
rate = 35 mL/min). After 32 min at 180°C, oven temperature was increased at 20°C/min 
to 225°C and held for 13.75 min. Total run time was 48 min. Injector and detector 
temperatures were at 270°C and 300°C, respectively. Individual fatty acids were 
identified using genuine external standards (Nu-Chek Prep, Inc., Elysian, MN). 
Synovial Fluid Analysis 
 Synovial fluid collected during the LPS challenge was analyzed for PGE2, CPII, 
and C2C using commercial ELISA kits previously validated for use in horses (Bertone et 
al., 2001; de Grauw et al., 2006).  The PGE2 assay was a 96-well microplate with an 
anti-mouse monoclonal antibody (R&D Systems, Inc., Minneapolis, MN).  Synovial 
fluid samples were diluted at 2:1, 1:2, 1:3, or 1:4 depending on time post-injection using 
calibrator diluent provided in the kit.  Following dilution, all procedures followed the 
protocol outlined by the kit.  The PGE2 ELISA had intra-assay precision between 5.0 
and 9.0% and inter-assay precision between 9.0 and 12.9%.   
 Also a 96-well microplate, the CPII commercial ELISA kit used a rabbit 
polyclonal antibody specific for CPII peptide (IBEX Pharmaceuticals Inc., Montreal, 
Quebec, Canada).  Synovial fluid samples were diluted using buffer III provided by the 
kit at 1:4, 1:5, 1:6 or 1:7 depending on time post-injection.  The protocol outlined by the 
kit was followed for all procedures.  The CPII plates ran with inter-assay precision 
within plates between 0.5% and 9.5% and intra-assay precision between plates between 
0% and 8.8%. 
 Finally, C2C commercial kits using a mouse monoclonal antibody ran with inter-
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assay precision between 0.6 and 9.5% and intra-assay precision between 1.0 and 6.0% 
(IBEX Pharmaceuticals Inc., Montreal, Quebec, Canada).  All samples were diluted on a 
1:3 dilution using buffer III provided in the kit.  Final concentrations of all markers were 
read using a microplate reader with optical density set at 450 nm (BioRad 680 
Microplate Reader, BioRad Laboratories, Hercules,CA).   
Statistical Analysis 
  All data were analyzed using the PROC MIXED method of SAS (SAS Inst. Inc., 
Cary, NC).  The model contained effects for treatment, time, knee, treatment by time, 
and treatment by time by knee interactions.  The model uses both RANDOM and 
REPEATED statements.  This covariance structure specifies a random effect of 
differences between animals and creates a correlation structure within animals that 
decreases with increasing amount of time between measurements (Littell et al., 1998).  A 
paired t-test was used to compare treatments at individual time points.  Significance was 
established for all variables at P ≤ 0.05 and P ≤ 0.10 was defined as a trend toward 
significance.  
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CHAPTER IV 
RESULTS 
 
Phase 1 
Physical Measurements 
 Wither height, hip height, BW, BCS, length, heart girth circumference and rump 
fat thickness were not affected (P > 0.40) by dietary treatment, but all physical 
measurements, with the exception of BCS, increased over time (P < 0.01; Table 3).   
Plasma Fatty Acid Concentrations 
A treatment by time interaction was observed for both isomers of CLA (P < 
0.01).  The c9,t11 isomer was detectable in LOW and HIGH horses by d 14 of 
supplementation with horses fed HIGH having greater (P = 0.04) concentrations.  
Similar results were observed for the t10,c12 CLA isomer with d 14 values tending to be 
greater (P = 0.08) in HIGH horses than LOW.  Concentrations of both CLA isomers in 
LOW horses peaked and plateaued d 14 after dietary treatments began, but 
concentrations continued to increase to d 42 for horses fed HIGH.  Plasma 
concentrations of both CLA isomers then declined (P < 0.01) in HIGH horses between d 
42 and 56 to levels similar to those observed at d 28.   
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Table 3.  Growth measurements of yearling horses fed increasing levels of CLA from d 0 to 56
1
. 
      Treatment
2
   
  
P-values
3
 
 Measurement Day CON (n = 6) LOW (n = 5) HIGH (n = 6) SEM Trt Time Trt * Time 
BW, kg 0 353 353 354.8 10.4 0.97 < 0.01 0.93 
 
7 358 361 360.4 
    
 
14 357 362 362.3 
    
 
21 361 364 365.6 
    
 
28 364 370 367.9 
    
 
35 367 374 371.0 
    
 
42 370 376 370.6 
    
 
49 371 374 371.0 
    
 
56 373 375 373.2 
    Wither height, cm 0 137 139.3 138.1 1.9 0.81 < 0.01 0.42 
 
7 139.2 140.0 139.0 
    
 
14 135.6 140.1 140.3 
    
 
21 139.9 140.3 141.3 
    
 
28 140.2 140.6 141.4 
    
 
35 140.9 141.2 141.6 
    
 
42 140.3 141.0 141.4 
    
 
49 140.7 141.0 141.7 
    
 
56 140.7 141.4 141.9 
    Hip height, cm 0 143.5 144.7 143.8 1.5 0.93 < 0.01 0.89 
 
7 143.9 145.4 144.7 
    
 
14 144.8 145.3 144.7 
    
 
21 145.4 146.2 145.5 
    
 
28 145.4 146.2 146.2 
    
 
35 145.7 146.7 146.4 
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Table 3. Continued 
      Treatment
2
       P-values
3
   
Measurement Day 
CON  
(n = 6) 
LOW  
(n = 5) 
HIGH  
(n = 6) SEM Trt Time Trt * Time 
 
42 145.7 146.4 146.5 
    
 
49 146.3 146.4 146.5 
    
 
56 147.9 147.7 147.6 
    Length, cm 0 147.2 146.2 145.2 1.7 0.97 < 0.01 0.73 
 
7 147.3 147.6 147.3 
    
 
14 149.0 148.2 149.0 
    
 
21 151.3 150.4 150.5 
    
 
28 151.5 150.6 150.7 
    
 
35 151.8 151.2 152.5 
    
 
42 152.3 152.4 153.8 
    
 
49 153.3 153.3 153.6 
    
 
56 153.3 153.7 153.6 
    Heart girth, cm 0 159.8 157.5 160.5 1.9 0.87 < 0.01 0.71 
 
7 160.3 160.0 161.7 
    
 
14 161.3 160.4 162.5 
    
 
21 162.2 162.2 163.3 
    
 
28 162.7 163.0 163.5 
    
 
35 163.0 163.0 163.8 
    
 
42 163.0 163.6 163.8 
    
 
49 163.9 162.8 164.0 
    
 
56 164.0 163.6 164.0 
    BCS 0 5.5 5.8 5.4 0.2 0.81 < 0.01 0.72 
 
7 5.4 5.7 5.4 
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Table 3. Continued 
      Treatment
2
       P-values
3
   
Measurement Day 
CON  
(n = 6) 
LOW  
(n = 5) 
HIGH  
(n = 6) SEM Trt Time Trt * Time 
 
14 5.4 5.7 5.6 
    
 
21 5.4 5.5 5.4 
    
 
28 5.6 5.7 5.5 
    
 
35 5.7 5.7 5.5 
    
 
42 5.5 5.4 5.5 
    
 
49 5.3 5.7 5.6 
    
 
56 5.8 5.9 5.8 
    Rump fat thickness, cm 0 0.28 0.29 0.28 0.01 0.78 < 0.01 0.79 
 
7 0.29 0.30 0.29 
    
 
14 0.29 0.30 0.30 
    
 
21 0.29 0.31 0.31 
    
 
28 0.31 0.32 0.33 
    
 
35 0.32 0.32 0.33 
    
 
42 0.32 0.32 0.33 
    
 
49 0.33 0.34 0.33 
      56 0.33 0.34 0.34         
 
1
Least square means  
2
Dietary treatments consisted of 1% diet soybean oil (CON), 0.5% diet soybean oil with 0.5% diet CLA (LOW), and 1% diet 
CLA (HIGH). 
3
Trt, treatment; Trt*time, treatment by time interaction 
 
 
 
 43 
 
 
Both CLA isomers (c9,t11; t10,c12) were affected by dietary treatment (P < 
0.01) with horses in the HIGH group having the greatest plasma concentrations, 
followed by LOW, with lowest concentrations observed in CON.  Horses fed CON had 
undetectable levels (minimum detectable level 0.0003%) of CLA throughout the 56 d 
trial, and both isomers increased over time in supplemented horses (HIGH and LOW; P 
< 0.01).  Figures 6 and 7 illustrate concentrations of c9,t11 and t10,c12 CLA isomers 
expressed as a  percentage of total fatty acid content.  Concentrations of 20:4, 
represented in Fig. 8, were also influenced by CLA supplementation with HIGH horses 
having lower (P < 0.01) concentrations than CON and tending to be lower (P = 0.06) 
than LOW.   
 
 
 
Figure 6. Changes in circulating levels of cis-9, trans-11 isomer of CLA in plasma 
(c9,t11; % total plasma fatty acid content) over time (d; least squares means ± SEM). 
Treatments were 1% diet soybean oil (CON; n = 6), 0.5% diet soybean oil with 0.5% 
diet CLA (LOW; n = 5), and 1% diet CLA (HIGH; n = 6).  
*, **, ***
 Superscripts denote a 
difference among treatments at each time (P < 0.05). 
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Figure 7. Changes in circulating levels of trans-10, cis-12 isomer of CLA in plasma 
(t10,c12; % total plasma fatty acid content) over time (d; least squares means ± SEM). 
Treatments were 1% diet soybean oil (CON; n = 6), 0.5% diet soybean oil with 0.5% 
diet CLA (LOW; n = 5), and 1% diet CLA (HIGH; n = 6). 
*, **,  ***
 Superscripts denote a 
difference among treatments at each time (P < 0.05) 
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Figure 8. Changes in circulating arachidonic acid levels in plasma (% total plasma fatty 
acid content) over time (d; least squares means ± SEM). Treatments were 1% diet 
soybean oil (CON; n = 6), 0.5% diet soybean oil with 0.5% diet CLA (LOW; n = 5), and 
1% diet CLA (HIGH; n = 6).   
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Additionally, plasma concentrations of 18:0 and 20:2 were influenced by dietary 
treatment (P = 0.04 and P = 0.02, respectively).  Stearic acid (18:0) concentrations were 
higher (P = 0.01) in LOW horses than CON, and increased (P < 0.01) in all horses over 
time, regardless of dietary treatment. Plasma concentrations of 20:2 were lower (P < 
0.01) in HIGH horses compared to CON, and also tended to increase (P = 0.08) over 
time for all horses, regardless of dietary treatment.  Plasma concentrations of other fatty 
acids changed over time, regardless of dietary treatment, and included: 16:0, 18:1, 18:2, 
18:3, and 22:6 (P < 0.01).  An overall increase over time (P ≤ 0.01) was observed for 
plasma concentrations of 16:0, 18:1, and 18:2 for all horses while concentrations of 18:3 
and 22:6 decreased (P < 0.01) over time with 18:3 showing a sharp decrease from d 0 to 
14.  Plasma fatty acid concentrations are illustrated in Table 4.
 47 
 
 
Table 4. Plasma fatty acid concentrations of yearling horses fed increasing levels of CLA from d 0 to 56.
1 
  
  Treatment
2
   
 
  P-values
3
   
Fatty Acid Day 
CON  
(n = 6) 
LOW  
(n = 5) 
HIGH  
(n = 6) SEM Trt Time Trt*Time 
14:0. % 0 0.27 0.27 0.20 0.08 0.71 0.76 0.07 
 
14 0.14 0.22 0.18 
    
 
28 0.24 0.24 0.10 
    
 
42 0.13 0.30 0.19 
    
 
56 0.19 0.11 0.43 
    16:0, % 0 10.57 9.66 7.63 1.25 0.37 0.01 0.02 
 
14 8.15 8.45 7.30 
    
 
28 10.47 10.75 8.68 
    
 
42 8.30 13.31 9.86 
    
 
56 9.59 9.99 12.95 
    16:1, % 0 0.29 0.27 0.44 0.21 0.09 0.43 0.54 
 
14 0.60 0.38 0.64 
    
 
28 0.96 0.37 0.32 
    
 
42 0.60 0.18 0.62 
    
 
56 0.38 0.09 0.19 
    18:0. % 0 13.24 12.86 12.87 1.39 0.04 < 0.01 0.29 
 
14 12.70 13.81 12.02 
    
 
28 13.47 15.44 15.20 
    
 
42 12.43 18.96 15.11 
    
 
56 14.39 19.17 17.86 
    18:1, % 0 8.39 7.22 7.65 1.07 0.33 0.01 0.16 
 
14 6.22 6.25 5.43 
    
 
28 7.23 7.59 7.52 
    
 
42 6.42 9.17 8.38 
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Table 4. Continued 
              Treatment
2
       P-values
3
   
Fatty Acid Day 
CON  
(n = 6) 
LOW  
(n = 5) 
HIGH  
(n = 6) SEM Trt Time Trt*Time 
 
56 7.32 8.25 11.52 
    18:1 trans-11, % 0 0.57 0.51 0.52 0.06 < 0.01 0.52 0.75 
 
14 0.54 0.50 0.39 
    
 
28 0.67 0.53 0.43 
    
 
42 0.59 0.54 0.40 
    
 
56 0.59 0.54 0.49 
    18:2, % 0 40.36 37.87 37.82 3.40 0.48 < 0.01 0.08 
 
14 40.16 41.15 35.67 
    
 
28 44.30 40.87 47.22 
    
 
42 42.21 50.74 47.81 
    
 
56 47.52 54.34 41.37 
    18:3, % 0 1.89 1.34 1.70 0.13 0.15 < 0.01 0.28 
 
14 0.86 0.74 0.77 
    
 
28 1.00 0.71 0.81 
    
 
42 0.92 0.87 0.89 
    
 
56 0.93 0.97 0.77 
    cis-9,trans-11 CLA, % 0 ND
4
 ND ND 0.13 < 0.01 < 0.01 < 0.01 
 
14 ND 0.68 1.02 
    
 
28 ND 0.92 1.96 
    
 
42 ND 0.80 2.47 
    
 
56 ND 0.92 1.69 
    trans-10,cis-12 CLA, % 0 ND ND ND 0.11 < 0.01 < 0.01 < 0.01 
 
14 ND 0.59 0.86 
    
 
28 ND 0.90 1.75 
    
 49 
 
 
Table 4. Continued 
              Treatment
2
       P-values
3
   
Fatty Acid Day 
CON  
(n = 6) 
LOW  
(n = 5) 
HIGH  
(n = 6) SEM Trt Time Trt*Time 
 
42 ND 0.73 2.15 
    
 
56 ND 0.90 1.62 
    20:1, % 0 0.28 0.22 0.22 0.04 0.47 < 0.01 0.16 
 
14 0.13 0.09 0.17 
    
 
28 0.20 0.12 0.25 
    
 
42 0.28 0.20 0.25 
    
 
56 0.28 0.26 0.21 
    20:2, % 0 0.26 0.21 0.16 0.05 0.02 0.08 0.73 
 
14 0.18 0.18 0.16 
    
 
28 0.27 0.18 0.18 
    
 
42 0.32 0.21 0.14 
    
 
56 0.33 0.31 0.20 
    20:4, % 0 0.87 0.83 0.79 0.09 0.02 0.5 0.78 
 
14 0.81 0.83 0.67 
    
 
28 0.94 0.77 0.74 
    
 
42 0.89 0.76 0.64 
    
 
56 0.82 0.82 0.54 
    20:5, % 0 ND 0.05 0.01 0.07 0.278 0.22 0.44 
 
14 ND ND ND 
    
 
28 ND 0.29 0.03 
    
 
42 ND ND ND 
    
 
56 ND ND ND 
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Table 4. Continued 
      Treatment
2
       P-values
3
   
Fatty Acid Day 
CON  
(n = 6) 
LOW  
(n = 5) 
HIGH  
(n = 6) SEM Trt Time Trt*Time 
22:6, % 0 1.42 2.12 1.92 0.55 0.59 < 0.01 0.79 
 
14 2.16 1.65 2.53 
    
 
28 1.11 0.89 1.10 
    
 
42 1.17 ND 0.50 
      56 0.74 0.03 0.40         
 
1
 Least square means 
2
 Dietary treatments consisted of 1% diet soybean oil (CON), 0.5% diet soybean oil with 0.5% diet CLA (LOW), and 1% diet 
CLA (HIGH) 
3
 Trt, treatment; Trt*time, treatment by time interaction 
4
 ND, not detectable (minimum detectable level is 0.0003%) 
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Phase 2 
Heart Rate, Respiration Rate and Rectal Temperature 
 During the LPS challenge, dietary treatment did not affect HR, RR and RT (P ≥ 
0.13), but all measurements were influenced by time post LPS injection (Fig. 9).  Both 
HR and RR decreased (P < 0.01) from PIH 0 to 6 h post-injection.  Maximum values for 
all three vital signs were recorded at 12 h post-injection, however returned to baseline 
levels by h 24.    
 
 
A) 
 
Figure 9.  Clinical assessment of heart rate (panel A), respiration rate (panel B), and 
rectal temperature (panel C) after intra-articular lipopolysaccharide (LPS; derived from 
Escherichia coli O55:B5) injection.  Treatments were 1% diet soybean oil (CON; n = 6), 
0.5% diet soybean oil with 0.5% diet CLA (LOW; n = 5), and 1% diet CLA (HIGH; n = 
6). *, ** superscripts denote differences between treatments at each time (P < 0.05). 
 
 
 
 52 
 
 
 
 
 
 
 
 
B) 
 
 C) 
 
 
Figure 9.  Continued 
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Carpal Circumference and Surface Temperature 
 
 A treatment by time interaction (P < 0.01) for carpal circumference was observed 
and characterized by delayed peak values in CON horses to h 168 when compared to 
peak values at h 24 by both the HIGH and LOW treatment groups.  Carpal 
circumference was not affected by dietary treatment or knee (P = 0.74), and because 
carpal circumference was not influenced by knee (P < 0.74), Fig. 10 represents 
combined mean carpal circumference for both the LRS and LPS joint.  There was an 
effect of time (P < 0.01) with peak circumference values noted at 24 h post-injection, 
followed by a decrease at h 168.  
 
 
 
Figure 10.  Carpal joint circumference (cm; least squares mean ± SEM) after intra-
articular lipopolysaccharide (LPS; derived from Escherichia coli O55:B5) injection at 
pre-injection h 0 and 6, 12, 24, 168, and 336 h post-injection. Treatments were 1% diet 
soybean oil (CON; n = 6), 0.5% diet soybean oil with 0.5% diet CLA (LOW; n = 5), and 
1% diet CLA (HIGH; n = 6).   
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 There was a tendency toward a dietary treatment by time interaction for carpal 
surface temperature (P = 0.10), which was evident at pre-injection h 0 and post-injection 
h 24.  Surface temperatures recorded at h 0 were higher (P < 0.01) for LOW horses 
versus HIGH, and tended to be higher (P = 0.06) than CON horses.  At 24 h post-
injection, the CON group’s carpal surface temperatures were lower (P = 0.03) than both 
HIGH and LOW horses.   
Carpal surface temperatures tended to be influenced by dietary treatment (P = 
0.10) with horses fed the LOW diet having higher surface temperatures than CON (P = 
0.04).  Since no effect of knee was noted (P < 0.27), Fig. 11 represents mean carpal 
surface temperatures for both carpal joints.  Regardless of dietary treatment, carpal 
surface temperatures were influenced by time (P < 0.01) with peak values noted at 6 h 
post-injection with an increase from baseline levels at h 0 (P < 0.01).  Values remained 
elevated at 12 h post-injection and fell from h 12 to 24 (P < 0.01) to levels tending to be 
below baseline (P = 0.06).   
   
 
 
 55 
 
 
 
Figure 11.  Carpal joint surface temperature (°C; least squares mean ± SEM) at pre-
injection h 0 and 6, 12, 24, 168, and 336 h post LPS injection. Treatments were 1% diet 
soybean oil (CON; n = 6), 0.5% diet soybean oil with 0.5% diet CLA (LOW; n = 5), and 
1% diet CLA (HIGH; n = 6).   
 
 
Synovial Fluid Biomarkers 
 Synovial PGE2 concentrations exhibited a time by knee interaction (P < 0.01), 
with the LPS knee showing greater changes in concentration over time compared to the 
LRS knee (Fig. 12).  Peak PGE2 concentrations were observed at 6 and 12 h post-
injection with a return to baseline by 168 h post-injection in the LPS knee.  In the LRS 
knee, concentrations peaked 24 h post-injection (P = 0.02) and returned to baseline by h 
168.  There was a significant knee effect with the LPS knee having greater (P = 0.01) 
PGE2 concentrations than the LRS knee.  Synovial PGE2 concentrations were not 
influenced by dietary treatment (P ≥ 0.15); however were affected by time (P < 0.01) 
with concentrations increasing to peak values at 6 h post-injection and decreasing to 
baseline by 336 h for all horses.   
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A)        B) 
 
Figure 12. Mean synovial fluid concentrations (pg/mL) of prostaglandin E2 (PGE2) over time (h) after intra-articular injection 
of 0.5 ng lipopolysaccharide (Panel A; LPS; derived from Escherichia coli 055:B5) or 0.8 mL sterile lactated Ringer’s solution 
(Panel B; LRS). Treatments were 1% diet soybean oil (CON; n = 6), 0.5% diet soybean oil with 0.5% diet CLA (LOW; n = 5), 
and 1% diet CLA (HIGH; n = 6). 
1
Trt, dietary treatment. 
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There was a treatment by time interaction (P = 0.03) for synovial fluid C2C 
concentrations, where, at PIH 0, HIGH horses had lower (P = 0.02) values than LOW, 
and CON horses tended to have lower concentrations (P = 0.10) than LOW horses (Fig. 
13).  Also, at 24 h post-injection, HIGH fed horses had lower concentrations than both 
the LOW and CON groups (P = 0.02 and P < 0.01, respectively). Synovial C2C 
concentrations were influenced by dietary treatment with horses in the HIGH group 
having lower (P = 0.01) concentrations than LOW.  There was also an effect of time (P 
< 0.01) with peak values seen at 12 and 24 h post-injection and returning to baseline by 
h 336.  Concentrations of C2C tended to be influenced by knee (P = 0.09) with the LPS 
injected joint having greater concentrations than the LRS joint over the 24 h challenge.  
Horses receiving the LOW dose CLA treatment tended to have higher (P = 0.10) 
synovial CPII concentrations than the other treatment groups.  Synovial concentrations 
of CPII also tended to be higher (P = 0.07) in samples from the LPS knee compared to 
LRS.  There was an effect of time (P < 0.01) with concentrations increasing (P = 0.03) 
from PIH 0 to h 12 followed by a sharp increase (P < 0.01) to peak values from 12 to 24 
h post-injection (Fig. 14).  Concentrations of CPII decreased (P < 0.01) from h 168 to 
336, but did not reach baseline values (Fig. 14).   
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A)        B) 
 
Figure 13. Mean synovial fluid concentrations (ng/mL) of collagen cleaving neopeptide (C2C) over time (h) after intra-
articular injection of 0.5 ng lipopolysaccharide (Panel A; LPS; derived from Escherichia coli 055:B5) or 0.8 mL sterile 
lactated Ringer’s solution (Panel B; LRS). Treatments were 1% diet soybean oil (CON; n = 6), 0.5% diet soybean oil with 
0.5% diet CLA (LOW; n = 5), and 1% diet CLA (HIGH; n = 6). 
1
Trt, dietary treatment.
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A)        B) 
 
Figure 14. Mean synovial fluid concentrations (ng/mL) of carboxypeptide of type II collagen (CPII) after intra-articular 
injection of 0.5 ng lipopolysaccharide (Panel A; LPS; derived from Escherichia coli O55:B5) or 0.8 mL sterile lactated 
Ringer’s solution (Panel B; LRS).  Treatments were 1% diet soybean oil (CON; n = 6), 0.5% diet soybean oil with 0.5% diet 
CLA (LOW; n = 5), and 1% diet CLA (HIGH; n = 6).  
1
Trt, dietary treatment. 
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CHAPTER V 
DISCUSSION 
 
 During the 56 d trial, BW, hip and wither heights, length, and heart girth 
circumference increased over time, which was expected for these yearling horses. The 
magnitude of increase in the first 21 d followed by a plateau is likely indicative of 
compensatory growth.  It is important to note that all horses were fed at or above 
requirements outlined by the NRC (2007).  Horses in the current study received 
approximately 22 Mcal/d DE compared to the 18 Mcal/d DE requirement for a 500 kg 
mature horse indicated by the NRC (2007).  As discussed by Hornick et al. (2000) 
through a compilation of studies, compensatory growth in livestock typically occurs 
within the first 30 d after an increase in the animal’s plane of nutrition, and data in the 
current study agrees with this assessment. The lack of a treatment effect across all 
physical parameters through the duration of the study supports isocaloric formulation of 
diets, and indicates that soybean oil and CLA supplements contribute similar energetics 
in the horse.  
In addition to the other physical measurements, there was also an increase in 
rump fat thickness over time, regardless of dietary treatment.  Previous research in pigs 
and mice indicates that CLA supplementation reduces adiposity; however, results with 
human CLA supplementation vary.  Weanling mice supplemented with 0.5% diet CLA 
had body fat values that were less than half the value of corn oil supplemented controls 
(Park et al., 1997).  In a similar study performed with grower-finisher pigs fed varying 
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levels of CLA, the impact of fat depth varied with body location with some areas having 
decreased fat thickness with increased CLA supplementation, and other locations not 
being affected (Thiel-Cooper et al., 2001).  Therefore, the singular measurement of rump 
fat in the current study may not give the best indication of body adiposity. Only one 
study evaluated the effect of dietary CLA on rump fat thickness in mature horses and 
produced similar results as the current study (Headley et al., 2011).  Additionally, it is 
possible that stage of growth and plane of nutrition has an effect on adipose versus lean 
deposition in the horse. 
 Plasma CLA concentrations were not detectable in the CON at any time point 
measured, which was expected since the CON diet contained no detectable levels of 
CLA.  Changes in plasma CLA concentrations in the current study for horses in the 
LOW group followed the same trend found by Headley et al. (2011) following dietary 
CLA supplementation to mature mares in which measureable levels were detected at d 
14 with peak concentrations at d 28.  Interestingly though, horses in the HIGH group did 
not follow the same trend, and had steady increases in plasma CLA concentrations to d 
42, followed by a notable decrease in circulating levels at d 56.  The decrease in CLA 
concentrations from d 42 to 56 may be explained by the inflammatory response caused 
by LPS injection affecting circulating fatty acid concentrations for the final 14 d of the 
study.  During peak inflammation, fatty acids are recruited from the phospholipid bilayer 
for the production of pro-inflammatory prostaglandins.  The re-filling of the 
phospholipid bilayer could potentially explain the reduction in circulating CLA levels in 
plasma.  The additional time effects observed in fatty acids other than CLA and 20:4 
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reveal the change in diet at the onset of the study.  The greatest magnitude of change in 
fatty acid concentrations occurred between d 14 and 42, and since it takes approximately 
28 d to fully adapt to a new source of dietary fat, this was to be expected (Julen et al., 
1995). 
Eicosadienoic acid (20:2), like 18:0, was affected by dietary treatment with lower 
concentrations in horses consuming HIGH compared to CON.  The CLA supplement 
contained greater concentrations of 20:2 than the soybean oil supplement; therefore, it is 
interesting that circulating concentrations were lower in horses that received the CLA 
supplement.  Muscle and adipose tissue of pigs showed similar results following 1% diet 
CLA supplementation where pigs supplemented with CLA had lower 20:2 
concentrations than those that received no CLA (Bee et al., 2008).  Lo Fiego et al. 
(2005) observed a reduction in 20:2 in similar tissues following supplementation of CLA 
at levels as low as 0.25% of the diet.  In further analysis of 20:2, Huang et al. (2011) 
found macrophages exposed to increased levels of 20:2 resulted in increased 20:4 
concentration and PGE2 production following treatment with LPS.  Therefore, the 
reduction of 20:2 in horses supplemented with CLA could support the hypothesis that 
CLA supplementation may reduce prostaglandin production during an inflammatory 
response. 
 Plasma levels of 20:4 were lower in horses supplemented with the HIGH dose of 
CLA when compared to both the LOW and CON.  This corresponds to findings by 
Headley et al. (2011) in which lower concentrations of 20:4 were measured in horses 
supplemented at the same level as the current study at 0.01% BW CLA than corn oil 
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supplemented controls.  In addition, 20:4 levels in breast tissue of broilers was lower in 
those that received the CLA supplement than both flaxseed and fish oil treatment groups 
(Shin et al., 2011).  In regards to LOW horses having similar 20:4 levels as CON, it may 
be that 0.5% diet CLA may not be sufficient to reduce circulating 20:4 levels in the 
horse.  During an inflammatory response, 20:4 present in cell membranes is converted to 
inflammatory prostaglandins, including PGE2, through the COX-2 pathway.  A 
successful reduction in circulating 20:4 levels through 1% diet CLA supplementation 
reduces the availability of a direct precursor to inflammation.   
Clinical responses of HR, RR, and RT recorded prior to arthrocentesis in the first 
24 h of the LPS challenge were unaffected by dietary treatment; however, the increased 
handling and stress of repeated arthrocentesis may explain the changes in vitals over the 
24 h period.  Values recorded at PIH 0 and post-injection h 24 were not different 
indicating that all vitals returned to baseline by 24 h post LPS injection.  Residual effects 
from sedation prior to arthrocentesis may explain the decreased values of each vital sign 
at 6 h post-injection.  Peak values at 12 h post-injection correspond to the increased 
inflammatory response as indicated by peak PGE2 concentrations, causing a slight, but 
noticeable increase in vital signs.  It is important to note, however, that vitals were never 
outside the normal range confirming that no animal had an adverse, systemic reaction to 
the LPS injection.   
 Carpal circumference and surface temperature values were also measured during 
the LPS challenge on both the LPS and LRS knees, using the LRS knee as a contralateral 
control.  The increase over time in carpal circumference without an effect of knee 
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indicates increased joint effusion from the initiation of an inflammatory response in both 
carpal joints.  The increased effusion reflected by increased carpal circumference in the 
LRS joint is likely due to repeated arthrocentesis and has been noted in other studies 
(van den Boom et al., 2005).  Both carpal joints had greatest values at 24 h post-
injection, which is consistent with findings in a similar study performed by Lucia et al. 
(2013) using LPS in weanling horses.   
 Increased surface temperatures during an inflammatory response are caused by 
hyperaemia at the site of inflammation due to increased metabolic waste accumulation 
(Bliss, 1998).  In the current study, carpal surface temperatures peaked at 6 and 12 h 
post-injection, which were expected due to the inflammatory response caused by LPS 
injection.  The peak temperature value coincides with peak PGE2 concentrations 
measured in the synovial fluid.  Surface temperatures in both knees returned to baseline 
levels by 24 h post-injection, which indicate a return to normal blood flow and reduction 
in inflammation.  This is one of the first uses of infrared images during an intra-articular 
LPS challenge, and values appear to correspond closely with inflammatory markers in 
synovial fluid. 
 Analyses of synovial fluid biomarkers indicate time effects for PGE2, CPII, and 
C2C, validating the LPS model and the ability to stimulate an acute and transient 
inflammatory response.  In addition, the LPS carpal joint had consistently greater 
concentrations of each biomarker compared to the LRS joint, further confirming the 
effectiveness of LPS to induce an acute inflammatory response.  Peak concentrations for 
PGE2, CPII and C2C relate to values previously recorded in studies performed by Lucia 
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et al. (2013) and de Grauw et al. (2009) measuring similar parameters in carpal joints of 
weanling and mature horses following intra-articular LPS injection.  Furthermore, both 
PGE2 and C2C returned to baseline prior to 336 h post-injection proving that 
inflammation caused by intra-articular LPS injection is transient. 
Prostaglandins released during an inflammatory response function to regulate 
inflammation.  Specifically, PGE2 has been determined as an excellent marker of equine 
joint disease, and has been used as a marker of inflammation in numerous studies in the 
horse (Bertone et al., 2001).  In regards to the effect of CLA on synovial PGE2 
concentrations, no treatment effect or treatment by time interaction was observed.  The 
limited number of horses in each treatment group may explain this lack of a treatment 
effect.  Following CLA supplementation to pigs using larger sample sizes, Changhua et 
al. (2005) found lower PGE2 concentrations in those supplemented with CLA (916.3 ± 
53.5 pg/mL) than the control diet (1211.0 ± 53.5 pg/mL) following systemic LPS 
injection.  The reduction in circulating 20:4 and 20:2 concentrations in the current study 
would suggest a potential to reduce the inflammatory response, as 20:4 is a direct 
precursor to prostaglandin production during inflammation.  Previous studies have 
confirmed incorporation of CLA into both lean and adipose tissues, indicating the 
possibility for CLA to successfully incorporate into synovial tissue where it could 
potentially decrease 20:4 levels and suppress the COX-2 pathway (Kramer et al., 1998; 
Thiel-Cooper et al., 2001).  Examination of the effects of dietary CLA supplementation 
on 20:4 levels in synovial fluid would provide a more direct indication of PGE2 
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precursor availability during inflammation.  At this time, further research is needed to 
determine the effects of CLA on the inflammatory eicosanoid PGE2. 
Although no dietary treatment effect was noted in synovial PGE2 concentrations, 
dietary CLA supplementation did have an effect on biomarkers of articular cartilage 
metabolism.  Following an inflammatory insult, the fibrous type II collagen begins to 
unwind and reveal hidden epitopes, including C2C, which can be used as a marker for 
articular cartilage degradation.  This epitope has been previously measured following 
exercise, LPS injection, and osteochondral fragmentation in horses (Frisbie et al., 2008; 
Lucia et al., 2013).  In the current study, there was an initial decrease in synovial C2C 
concentrations from PIH 0 to 6 h post-injection, which is likely due to a shift in cartilage 
metabolism at the onset of an inflammatory response.  The same decrease from PIH 0 to 
6 h post-injection was observed in a similar study performed by Lucia et al. (2013) 
following LPS injection in weanling horses.  Peak C2C values were observed at 24 h 
post-injection, which is consistent with peak times recorded by Lucia et al. (2013) and 
de Grauw et al. (2009).  Peak concentrations of C2C in the current study are similar to 
those recorded by Lucia et al. (2013) using weanling horses.  
A reduction in type II collagen degrading biomarker, C2C, was observed in 
horses fed HIGH CLA when compared to the LOW dose.  This demonstrates less 
cartilage degradation when horses received 1% diet CLA supplementation prior to LPS 
administration.  At PIH 0, HIGH horses had lower C2C concentrations than LOW, 
which can be attributed to the previous 42 d of CLA supplementation.  Furthermore, at 
24 h post-injection when peak values were recorded, HIGH fed horses had lower 
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concentrations of C2C compared to both LOW and CON horses.  This indicates CLA 
supplemented at 1% diet is effective in reducing cartilage degradation both prior to and 
during an inflammatory insult. 
 When type II collagen degrades, there is an attempt to repair the fibers.  During 
this repair, CPII is released from the type II collagen precursor, procollagen, and can be 
used as a marker of type II collagen regeneration.  This biomarker is often used as a 
measurement to counter the degradative marker C2C.  Concentrations of CPII peaked at 
24 h post-injection, which agrees with both Lucia et al. (2013) and de Grauw et al. 
(2009).  Peak values recorded in the current study more closely resemble those seen by 
Lucia et al. (2013) in weanling horses, which are lower than those recorded by de Grauw 
et al. (2009) using mature horses.  It is expected that yearling horses would have values 
similar to weanlings as opposed to mature horses (5 to 8 y).  Unlike PGE2 and C2C, 
concentrations of CPII in the current study did not return to baseline levels by 336 h 
post-injection, which was not anticipated since CPII concentrations in weanlings 
following LPS injection returned to baseline by 336 h post-injection (Lucia et al., 2013).  
This delay indicates recurring cartilage regeneration at 2 wk following LPS injection.  
An additional sample could have provided baseline measurements; however, 
concentrations of CPII were on the decline by 336 h post-injection.   
In regards to the effect of CLA on cartilage metabolism, there was a tendency 
toward a treatment effect for CPII, indicating that horses fed the LOW dose CLA had 
greater cartilage regeneration than CON fed horses.   No previous studies have yet been 
performed to determine the effects of CLA on the metabolism of type II collagen; 
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however, a similar study was performed to determine the effect of oral glucosamine 
supplementation on inflammation in yearling horses using the LPS model (Lucia, 2013).  
Lucia (2013) found that oral glucosamine reduced synovial PGE2 and C2C, but increases 
CPII concentrations in carpal joints challenged with LPS.   Although this gives little 
insight into the effectiveness of dietary CLA, it does support the potential of CLA to 
reduce inflammation and cartilage degradation while increasing cartilage repair through 
dietary supplementation in the horse.   
  
 69 
 
 
CHAPTER VI 
 
SUMMARY 
 
 
 
Based on these results, horses that received CLA supplementation had less 
cartilage degradation and tended to have greater cartilage regeneration when 
inflammation was induced via LPS, but there was no effect on PGE2 concentrations.  The 
results of fatty acid analysis, in particular reduction of 20:4, and cartilage metabolism, 
however, support the hypothesis that CLA may be capable of reducing inflammation.  
There are multiple biomarkers for inflammation, and PGE2 was chosen due to its 
relationship to fatty acids, and its reliability as an indicator of joint disease (Bertone et 
al., 2001).  The lack of a response by PGE2 to CLA treatment may be explained by 
individual response to inflammation, as well as the small sample sizes in the current 
study.  Therefore, in future studies, it may be beneficial to have larger numbers of 
animals to account for the individual variability if PGE2 is the marker of choice. 
  Both 20:4 and 20:2 were measured at lower circulating concentrations in horses 
that received the HIGH dosage of CLA at 0.01% BW.  The successful reduction in 
circulating 20:4 levels may reduce precursor availability to inflammatory prostaglandins, 
including PGE2.  Huang et al. (2011) confirmed the pro-inflammatory effects of 20:2 in 
mice macrophages, and its reduction in circulating levels could provide further evidence 
into CLA’s capability to mitigate inflammation.  Additionally, further research is needed 
to determine the effects of CLA on adiposity in the young horse.  Because horses in the 
current study showed evidence of compensatory growth, this may have been a poor 
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model to determine effects on fat deposition.   Further study of dietary CLA inclusion in 
the horse may require a longer period of supplementation, evaluation of body fat 
deposits other than just rump fat, or mature horses in a more obese condition.  In 
conclusion, dietary CLA supplementation may be a method to mitigate inflammation 
and cartilage metabolism in young horses.  Dietary CLA was well accepted by horses, 
beneficially altered plasma fatty acid concentrations, and decreased cartilage degradation 
when acute inflammation was induced.  Therefore, during an inflammatory response, 
CLA has the potential of delaying or minimizing cartilage turnover, and may have 
application for OA models and exercising horses. 
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APPENDIX A 
EXTRACTION AND METHYLATION OF FATTY ACIDS 
 
Extraction 
 Feed samples were dried and ground, and 5 g of both hay and grain were added 
to a 50 mL tube with 10 mL 2:1 chloroform:methanol Folch solution to extract the lipid.  
Each feed sample was homogenized using a Polytron homogenizer for 1 min, and 
allowed to sit on a shaker for 6 hours.  Feed samples were then filtered through a 
Whatman filter apparatus using 2.4 cm GF/C filters into a second 50 mL tube.  
Approximately 8mL of 74% KCl was added to every sample, vortexed and then 
centrifuged for 30 min at ½ max speed. Plasma samples were extracted similarly, with 1 
mL homogenized in 10 mL Folch solution for 1 min.  Each plasma sample received 5 
mL 74% KCl, and also centrifuged for 30 min at ½ max speed.  Lastly, the bottom 
chloroform phase containing the extracted lipid was removed from all samples and 
transferred to 20 mL test tubes.   
Methylation 
 All feed and plasma samples were methylated using the same protocol.  After the 
chloroform phase was dried using N-evap at 40°C, the lipid was saponified and 
methylated by adding 1 mL of 0.5 N KOH in MeOH and heated in a 70°C water bath for 
10 min to separate the fatty acids.  Next, 1mL of 14% BF3 in MeOH was added to each 
sample, flushed with N2 and placed in a 70°C water bath for 30 min.  Finally, the fatty 
acids were constituted in hexane by adding 2 mL hexane to each sample with 2mL 
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saturated NaCl and vortexed.  The top phase was transferred to a 20 mL tube containing 
approximately 1 g of NaSO4 to remove any remaining H2O from the sample.  This step 
was repeated twice and all hexane was transferred to a glass scintillation vial, dried, 
reconstituted with 500 μL hexane and placed in a GC vial for analysis using the gas 
chromatograph. 
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APPENDIX B 
ELISA PROTOCOL 
 
PGE2 
 All synovial fluid samples were diluted with calibrator diluent provided by the 
commercial PGE2 ELISA kit (R&D Systems, Inc., Minneapolis, MN) prior to plating 
depending on collection time post-injection.  Synovial fluid samples taken at 
preinjection h 0 and 6, 24, 168 and 336 h postinjection had dilutions of 2:1, 1:2, 1:3, 1:2, 
and 2:1, with diluent provided by the manufacturer, respectively. At 12 h postinjection, 
1:3 and 1:4 dilutions were used for CON and LPS joints, respectively due to the greater 
variability in PGE2 concentrations at this time point.    
The diluted synovial fluid was pipetted at 150 µL into each well with 50 µL of mouse 
monoclonal antibody to PGE2, and allowed to incubate for 1 h at room temperature on 
an orbital microplate shaker (VWR Microplate Shaker 120 V, Henry Troemner, LLC, 
Thorofare, NJ) at 525 rpm.  Following the incubation period, 50 µL of a horseradish 
peroxidase-labeled PGE2 was added to each well and allowed to incubate for 2 h on the 
orbital microplate shaker at 550 rpm.  The 96 well microplate was washed using a wash 
buffer, and 200 µL of a color reagent was added and allowed to sit for 30 min.  Each 
well received 100 µL of a stop solution and a microplate reader with optical density set 
at 450 nm was used to read each plate (BioRad 680 Microplate Reader, BioRad 
Laboratories, Hercules,CA). 
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C2C 
 The C2C ELISA is a 96 well plate coated with C2C peptide conjugate within a 
stabilizing matrix (IBEX Pharmaceuticals Inc., Montreal, Quebec, Canada).  A test plate 
was used to determine optimum dilutions for time points and treatment joints.  All 
synovial fluid samples were run on a 1:3 dilution.  Diluted samples were plated at 50 μL 
in each well on the polypropylene mixing plate with 50 μL of a C2C antibody and 
allowed to pre-incubate for on an orbital microplate shaker (VWR Microplate Shaker 
120 V, Henry Troemner, LLC, Thorofare, NJ) for 30 min at 650 rpm.  Following pre-
incubation, 80 μL of the sample mixture was transferred to the ELISA microplate and 
incubated on the orbital microplate shaker for 1 h at 650 rpm.  The ELISA microplate 
was washed 3x using the provided wash buffer and 100 μL of a goat anti-mouse 
horseradish peroxidase was added to each well.  Following another 30 min incubation on 
the orbital microplate shaker at 650 rpm, the ELISA microplate was washed 6x using the 
provided wash buffer and 100 μL of the color reagent was added to each well.  The 
ELISA microplate was incubated a final time on the orbital microplate shaker at 650 rpm 
for 30 min.  Finally, 100 μL of a stop solution was added and a microplate reader was 
used to determine concentration with an optical density at 450 nm.  
CPII 
The CPII ELISA is a 96-well microplate coated with bovine CPII antigen (IBEX 
Pharmaceuticals Inc., Montreal, Quebec, Canada).  Dilutions did have to be modified 
based on time postinjection for the concentrations in synovial fluid.  Synovial fluid from 
both the LRS and LPS joints at pre-injection h 0 were diluted with Buffer III with a 1:4 
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dilution.  Some samples were more concentrated and required a 1:5 dilution.  LPS and 
LRS samples taken at 6 and 336 h postinjection were run on a 1:4 dilution.  Samples 
from 12 h postinjection were diluted 1:4 and 1:5 for CON and LPS joints, respectively.  
At 24 h postinjection, CPII concentrations were expected to be the highest; therefore, 
dilutions of 1:6 and 1:7 were used for CON and LPS joint samples, respectively.  Lastly, 
postinjection h 168 CON samples were diluted at 1:4, and LPS samples were diluted at 
1:5.   
After diluting the synovial fluid samples in Buffer III and plating each sample on 
a polypropylene mixing plate, 50 μL of a rabbit polyclonal antiserum specific for CPII is 
added and allowed to pre-incubate for 1 h on an orbital microplate shaker (VWR 
Microplate Shaker 120 V, Henry Troemner, LLC, Thorofare, NJ) at 650 rpm prior to 
transferring the mixture to the ELISA microplate.  Once on the ELISA microplate, the 
sample was allowed to incubate for 2 h on the orbital microplate shaker at 650 rpm.  The 
microplate was then washed 6x using a wash buffer provided with the kit.  Each well 
received 100 μL of a goat anti-rabbit horseradish peroxidase conjugate and placed on the 
orbital microplate shaker at 650 rpm for 30 min.  The microplate was washed 6x again 
using the provided wash buffer and 100 μL of the color reagent was added.  After an 
additional 30 min at 650 rpm on the orbital microplate shaker, a stop solution was added 
and a microplate reader with wavelength set at 450 nm was used to read the 
concentrations. 
 
 
